Inventor · disambiguated record
Mary-Lee Dequeant
Also filed as: DEQUEANT MARY-LEE · DEQUÉANT MARY-LEE
8 granted patents·13 pending applications·10 citations·filing 2019–2025
81Inventor score
Top patents by PatentIndex Score
21 records- 0194US11254912B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Granted Feb 22, 2022·5 cites·14 claims
- 0293US11497773B2Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Granted Nov 15, 2022·2 cites·20 claims
- 0392US11649438B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Granted May 16, 2023·2 cites·18 claims
- 0489US11679130B2Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Granted Jun 20, 2023·1 cites·29 claims
- 0582US11857574B2Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2022·Granted Jan 2, 2024·0 cites·21 claims
- 0677US11679131B2Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Granted Jun 20, 2023·0 cites·29 claims
- 0774US2022090012A1Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 0874US2025179146A1Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistenceCRISPR THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0973US12227763B2Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2019·Granted Feb 18, 2025·0 cites·9 claims
- 1069US2025027087A1Modulating expression of alas1 (5'-aminolevulinate synthase 1) geneCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1168US2025257320A1Methods and compositions for treating cancerCRISPR THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 1264US11795238B2Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptorCRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 24, 2023·0 cites·20 claims
- 1362US2023303713A1Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereofCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1462US2024041757A1LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERYCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1559US2023390392A1Multiplex gene edited cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1658US2023046228A1Methods for manufacturing genetically engineered car-t cellsCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1755US2022387488A1Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignanciesCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1855US2022378829A1Genetically engineered immune cells targeting cd70 for use in treating solid tumorsCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1948US2022387571A1Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 2048US2023355761A1Cd70+ solid tumor therapy using genetically engineered t cells targeting cd70CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 2148US2022387572A1Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70CRISPR THERAPEUTICS AG·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mary-Lee Dequeant files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →